Statement on Compassionate Use
In our quest to create a world without ALS, The ALS Association believes that people with ALS should have access to effective treatments as quickly as possible. Our primary core value is that people with ALS and their families come first in everything we do. When it comes to advancing therapies for ALS, we work with all stakeholders in an effort to find the best path forward.
We realize that time is the most precious commodity for people living with ALS. For this reason, we are working closely with academic institutions and pharmaceutical companies developing potential treatments for ALS. Our goal is to facilitate clinical trials and accelerate the availability of treatments, including access to compassionate use programs in our discussions with these organizations.
The ALS Association is committed to helping make promising treatments available as quickly as possible. We will continue to communicate with academic institutions and pharmaceutical companies about the needs and concerns of people with ALS and their families. In the meantime, it is absolutely critical that people with ALS continue to participate in clinical trials. Ultimately, patient enrollment and participation in clinical trials is the only way to determine the effectiveness of treatments for this devastating disease.